<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877965</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102130</org_study_id>
    <secondary_id>NICHD-2018-DGX01</secondary_id>
    <secondary_id>HHSN27500002</secondary_id>
    <nct_id>NCT03877965</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease</brief_title>
  <acronym>DGX01</acronym>
  <official_title>Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christoph P Hornik, MD MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open-label, PK and safety profile study of enteral
      digoxin in children &lt;6 months old at time of enrollment, post-surgical or hybrid stage 1
      palliation, but prior to surgical stage 2 palliation.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of dixogin</measure>
    <time_frame>Approximately 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related to study procedures and serious, unexpected, suspected adverse reactions related to digoxin</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with tachyarrythmias</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with second and third degree atrioventricular conduction block</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with sinus bradycardia</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with need for temporary or permanent pacing</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of death</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR interval</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Derived from electrocardiograms and their reports performed per standard of care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS duration</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Derived from electrocardiograms and their reports performed per standard of care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT interval</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Derived from electrocardiograms and their reports performed per standard of care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected QT interval using Bazett's formula</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Derived from electrocardiograms and their reports performed per standard of care</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentration of NT-proBNP</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentration of MR-proANP</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular end diastolic volume</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular end systolic volume</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular ejection fraction</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular shortening fraction</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular end diastolic dimension</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular end systolic dimension</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular fractional area change</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Degree of atrioventricular valve regurgitation</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Qualitative right ventricular or left ventricular function assessment</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary to systemic blood flow ratio</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary vascular resistance</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean pulmonary artery pressure</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular end diastolic pressure</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular or left ventricular end systolic pressure</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Right and left pulmonary artery size</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Pressure gradients across the aortic arch</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>As measured by cardiac catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of unplanned surgical intervention</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Including cannulation for mechanical circulatory support</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of listing for heart transplant</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of receiving heart transplant</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay after S1P</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of days on mechanical ventilation after S1P</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospital readmissions from S1P discharge to S2p</measure>
    <time_frame>Approximately 7 months</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Children with single ventricle congenital heart disease</arm_group_label>
    <description>Receiving digoxin per standard of care during the interstage period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses</description>
    <arm_group_label>Children with single ventricle congenital heart disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be collected to assess pharmacokinetic and biomarker levels
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 48 infants diagnosed with single ventricle congenital heart disease, receiving
        digoxin per standard of care during the interstage period
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of single ventricle congenital heart disease

          -  Status post-surgical or hybrid stage 1 palliation but prior to surgical stage 2
             palliation

          -  Age â‰¤ 30 days of life at time of stage 1 palliation

          -  Age &lt; 6 months at time of enrollment

          -  Require treatment with enteral digoxin per their treating medical provider if their
             planned maintenance treatment dosing regimen is within the labeled dose range of 7.5 -
             20 mcg/kg/day divided in 2 or 3 equal doses

          -  Informed consent from parent(s) or legal guardian(s)

        Exclusion Criteria:

          -  Serum creatinine &gt; 2 mg/dL at enrollment

          -  Diagnosis of second degree or higher atrioventricular conduction block at enrollment

          -  Diagnosis of clinically significant sinus bradycardia requiring intervention at
             enrollment

          -  Known hypersensitivity to digoxin or other forms of digitalis

          -  Extracorporeal life support (i.e., ECMO, dialysis, ventricular assist device) at
             enrollment

          -  Received digoxin prior to enrollment

          -  Received or anticipated to receive a loading dose of digoxin.

          -  Any condition that would make the participant, in the opinion of the investigator,
             unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christoph Hornik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Childrens Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital of New York Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Christoph P Hornik, MD MPH</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

